Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib

BACKGROUND: Although kinase inhibitors (KIs) are generally effective, their use has a large impact on the current health care budget. Dosing strategies to reduce treatment costs are warranted. Boosting pharmacokinetic exposure of KIs metabolized by cytochrome P450 (CYP)3A4 with ritonavir might resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Boosman, René J., de Gooijer, Cornedine J., Groenland, Stefanie L., Burgers, Jacobus A., Baas, Paul, van der Noort, Vincent, Beijnen, Jos H., Huitema, Alwin D.R., Steeghs, Neeltje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964029/
https://www.ncbi.nlm.nih.gov/pubmed/35352280
http://dx.doi.org/10.1007/s11095-022-03244-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964029/
https://www.ncbi.nlm.nih.gov/pubmed/35352280
http://dx.doi.org/10.1007/s11095-022-03244-8

Ejemplares similares